Nexien Biopharma Inc

Nexien BioPharma, Inc. Engages CORE IR for Investor Relations, Public Relations and Shareholder Communications Services

Nexien BioPharma, Inc. Has Been Issued a U.S. Patent for the Methods and Compositions for Treating Non-Dystrophic Myotonia and Myotonic Dystrophies Types 1 and 2

Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity - two common nerve agents

Nexien BioPharma to Present at The MicroCap Conference Spring Investor Summit on Tuesday, April 2nd

Nexien BioPharma Announces Acceptance of Patent Application No. 238946 by Israeli Patent Office